Dashboard/AGARWALEYE

AGARWALEYE

OVERVALUED

Dr. Agarwal's Health Care Limited

Healthcare · NSE

↓ 757.9% vs fair value

52W Low

₹327

+46.4% from low

52W High

₹568

-15.7% from high

News sentiment

4 bull25 neu0 bear

✦

Analyst Note

4d ago

Dr. Agarwal's Health Care Limited is currently overvalued by 94% compared to our calculated fair value of ₹56. The company's return on capital employed (ROCE) has been deteriorating, standing at 8.4% in the latest year. Sentiment has turned bearish over the last week despite a bullish 30-day trend. This stock is suitable for conservative investors seeking stable returns.

0 articles

No company news found yet.

Valuation Gauge

OVERVALUED-757.9% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹479

Fair Value

₹56

Fair Value Analysis

₹56

Based on balance sheet strength analysis and earnings growth potential for Healthcare sector companies | Sector-expensive: P/E at 95th percentile vs sector peers. | CAUTION: ROCE declining (latest 16.4%) — returns on capital are falling; verify this isn't a value trap.

Low confidence

Balance Sheet Value

33% weight

₹55

Growth Valuation

67% weight

₹56

Price vs Market

AGARWALEYE

Nifty 50

Technical Pulse

Plain English — no jargon

RSI 66.4Bullish

52-week range-2% from high

L 401H 490.95

20-day avg₹452▲ 6.4%

50-day avg₹441▲ 9.2%

📍

Price PositionNeutral

Not enough price history to assess trend.

💪

Momentum (RSI)Overbought

RSI is 66 — overbought territory. Buying has been aggressive, a pullback is possible.

📈

Short-term TrendBullish

Above both 20-day and 50-day averages — short-term momentum is positive.

↑Combined Verdict

Expensive and overbought — the stock is trading well above fair value with stretched momentum. High risk of a correction. Not a good entry point.

Shareholding Pattern

Stock Health Score

Solid Fundamentals

6.9 / 10

Profitability

5/10

EPS of ₹4.0 — ROE data unavailable for full scoring

Debt & Leverage

10/10

D/E ratio of 0.5x is well within the Healthcare sector norm of 0.8x — strong balance sheet

Valuation vs Peers

8/10

P/E of 112.9x is slightly below the Healthcare sector median of 160x — reasonably valued

Cash Flow

4/10

FCF margin of 2.3% — thin cash generation, watch capex trends

Earnings Growth

10/10

5yr EPS CAGR of 30.3% is well above the Healthcare sector average of 18.7% — strong growth

Dividend

4/10

No dividend — typical for growth-stage companies

Company Health Timeline

10-year financial health at a glance

FY20

FY21

FY22

FY23

FY24

FY25

Revenue Growthⓘ

OPM %ⓘ

Net Profitⓘ

Free Cash Flowⓘ

ROE %ⓘ

ROCE %ⓘ

Debt / Equityⓘ

Interest Cov.ⓘ

Health Score

Strong

Moderate

Weak

Poor

No data

Sentiment Trend

Not enough data yet

Historical Returns

Key Ratios & Growth

FCF Yield

-2.1%

Free cash flow / market cap

Operating Cash Flow

₹360 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹4

P/E Ratio

112.9x

P/B Ratio

9.6x

ROE

—

ROCE

8.4%

Debt / Equity

0.49x

Beta

—

Div Yield

—

FCF (Cr)

₹39 Cr

Revenue (Cr)

₹1,705 Cr

EPS Growth 5Y

30.3%

Mkt Cap (Cr)

₹14,266 Cr

52W High

₹568

52W Low

₹327

Book Value/Share

₹47

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
TTM	₹2.0K Cr	₹539 Cr	27.0%	₹161 Cr	₹3.99
2025-03-31	₹1.7K Cr	₹463 Cr	27.0%	₹110 Cr	₹2.64
2024-03-31	₹1.3K Cr	₹367 Cr	28.0%	₹95 Cr	—
2023-03-31	₹1.0K Cr	₹275 Cr	27.0%	₹103 Cr	—
2022-03-31	₹696 Cr	₹186 Cr	27.0%	₹43 Cr	—
2021-03-31	₹471 Cr	₹85 Cr	18.0%	₹-59 Cr	—
2020-03-31	₹531 Cr	₹124 Cr	23.0%	₹-21 Cr	—

Compounded Growth Rates

Sales Growth

3Y+24.7%

5Y+33.2%

10Y—

Profit Growth

3Y+16.1%

5Y—

10Y—

EPS Growth

3Y—

5Y—

10Y—

Peer Comparison

Healthcare

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
AHCL Anlon Healthcare Limited	₹13.9	₹50.7	+72.6%	20.5	7.3%	UNDERVALUED
ALPA Alpa Laboratories Limited	₹69.8	₹196.4	+64.5%	12.8	13.4%	FAIRLY_VALUED
ASTERDM Aster DM Healthcare	₹755.4	₹1,585.8	+52.4%	117.6	7.9%	UNDERVALUED
VIMTALABS Vimta Labs Limited	₹453	₹722.6	+37.3%	26.2	18.6%	UNDERVALUED
UNICHEMLAB Unichem Laboratories Limited	₹372.6	₹592.5	+37.1%	8.9	12.1%	FAIRLY_VALUED
DCAL Dishman Carbogen Amcis Limited	₹195.5	₹281.2	+30.5%	25.6	1.9%	FAIRLY_VALUED
INDRAMEDCO Indraprastha Medical Corporation Limited	₹358.2	₹462.6	+22.6%	18.5	20.6%	UNDERVALUED
MOREPENLAB Morepen Laboratories Limited	₹43	₹52.8	+18.5%	23.3	10.8%	FAIRLY_VALUED

Institutional Activity

Bulk deals, block deals, short selling & delivery volume — NSE data

Insider Trading

Community Pulse

What is Dalal Street saying?

r/IndiaInvestments · r/Dalal_Street_Investments · r/IndianStockMarket

No Reddit mentions found yet for AGARWALEYE.

StockTwits

What traders are saying right now

StockTwits

No StockTwits activity found for AGARWALEYE.

Search Interest

Google Trends · India · Last 90 days

Trends

Trend data not yet available — check back soon.

Telegram Channels

ET Markets · CNBC TV18 · Moneycontrol · Zee Business · NDTV Profit

No Telegram mentions found yet for AGARWALEYE.

Exchange Filings

BSE announcements · last 90 days

NSE ↗BSE ↗

Loading filings…

Share this Stock

Download card · Share on WhatsApp

Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant